Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Methylone in Healthy Subjects
NCT06303648Phase 1Completed
- Sponsor
- Transcend Therapeutics
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of methylone in post-traumatic stress disorder (PTSD) (5 cohorts), sponsored by Transcend Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration for methylone at 48 hours and Area under the plasma concentration-time curve for methylone at 48 hours. Started Mar 2024; status: completed.
02
Drugs
methylone
03
Conditions
post-traumatic stress disorder (PTSD)
Beyond the preview
Go deeper on NCT06303648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06303648.